Former BridgeBio exec launches new anti-inflammatory biotech with $169M, but is mum on what exactly it's doing

Lei Lei Wu

News Reporter

Paragon Therapeutics, an antibody engineering company, has spun out its anti-inflammatory antibodies into Apogee Therapeutics, which launched out of stealth Wednesday morning with a Series …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Former BridgeBio exec launches new anti-inflammatory biotech with $169M, but is mum on what exactly it's doing

Lei Lei Wu

News Reporter

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech industry worries over potential for RFK Jr. ally as FDA pick

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Charles River to close ‘15 smaller sites’ as demand for early research declines

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

For­mer Bridge­Bio ex­ec launch­es new an­ti-in­flam­ma­to­ry biotech with $169M, but is mum on what ex­act­ly it's do­ing

Lei Lei Wu

News Reporter

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Former BridgeBio exec launches new anti-inflammatory biotech with $169M, but is mum on what exactly it's doing

Biotech industry worries over potential for RFK Jr. ally as FDA pick

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Charles River to close ‘15 smaller sites’ as demand for early research declines

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks